Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1

Status

Recruiting 21Active not recruiting 16Completed 13Not yet recruiting 7Terminated 3Withdrawn 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Other hematologic neoplasm 3Myeloid 2Lymphoid 1

Conditions

Myelodysplastic Syndromes 2Leukemia, Myeloid, Acute 2Leukemia, Myelogenous, Chronic, BCR-ABL Positive 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Myeloproliferative Disorders 1Lymphoma, Non-Hodgkin 1Lymphoma 1Leukemia 1Hodgkin Disease 1Hematologic Neoplasms 1

Interventions

pembrolizumab 116Carboplatin 48Nivolumab 46Paclitaxel 35Cyclophosphamide 35Cisplatin 34Gemcitabine 30atezolizumab 25Specimen Handling 25venetoclax 24Pemetrexed 24Magnetic Resonance Spectroscopy 24fludarabine 22Ipilimumab 22Docetaxel 22Bevacizumab 22Biopsy 21Radiotherapy 20Azacitidine 20Fluorouracil 19Dexamethasone 19Radiosurgery 18durvalumab 17Leucovorin 16olaparib 14Trastuzumab 14Cetuximab 14Capecitabine 14fludarabine phosphate 13Lenalidomide 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Terminated × Busulfan × 1 year × Clear all
NCT01135329 2026-05-27

Reduced-intensity, Related-donor Bone Marrow Transplantation Followed by High-dose Cyclophosphamide for Hematologic Cancers

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase 2 Terminated
15 enrolled 8 charts
LymphoidMyeloidOther hematologic neoplasm

Hodgkin Disease, Leukemia, Lymphoma, Lymphoma, Non-Hodgkin, Myelodysplastic Syndromes, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT01366612 2026-04-03

FLUBUTBI

Hackensack Meridian Health

Phase 3 Terminated
53 enrolled 11 charts
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute

NCT05579769 2025-10-02

Pediatric Study of GVHD Ppx w/o Calcineurin Inhibitors After Day60 Post First Allo HSCT for Hematological Malignancies.

St. Jude Children's Research Hospital

Phase 2 Terminated
3 enrolled 10 charts
Other hematologic neoplasm

Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡